Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Dexcel-Pharma Ltd., 7 Sopwith Way, Drayton Fields, Daventry, Northamptonshire NN11 8PB, UK
Hyoscine hydrobromide is thought to act as an anticholinergic agent by both cutting off stimuli to the vestibular apparatus, and also by acting directly on the vomiting centre.
Hyoscine hydrobromide is readily absorbed from the gastro-intestinal tract, and in circulation is bound to plasma proteins. Clinical studies have shown that oral hyoscine hydrobromide is effective in preventing motion sickness at plasma concentration of 50 pg/ml (equivalent to 0.17 nmol/1). This concentration is reached within 30 minutes following oral/buccal administration of 0.3 mg hyoscine hydrobromide and it is effective for about 4 hours. Hyoscine hydrobromide is almost entirely metabolised in the body.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
